Status:
UNKNOWN
Effect of Bevacizumab on Asymptomatic Radiotherapy-induced Brain Injury
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Conditions:
Brain Injuries
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
To investigate the effect of Bevacizumab on asymptomatic radiotherapy-induced brain injury patients with head and neck cancer.
Detailed Description
Radiotherapy-induced brain injury (RI) is a serious complication of radiotherapy in head and neck cancer (HNC) patients. Previous studies have confirmed that Bevacizumab has a good effect on patients ...
Eligibility Criteria
Inclusion
- Head MRI confirmed RI lesions. Sign the informed consent.
Exclusion
- With clinical symptoms of RI lesions. Head MRI showed bleeding lesions Contraindications of Bevacizumab. Pregnant women and parturient women.
Key Trial Info
Start Date :
November 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2025
Estimated Enrollment :
204 Patients enrolled
Trial Details
Trial ID
NCT05303259
Start Date
November 1 2021
End Date
December 30 2025
Last Update
March 31 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-Sen Memorial Hospital
Guangzhou, Guangdong, China, 510120